New EU Filings
Executive Summary
Janssen's talquetamab for the treatment of patients with relapsed or refractory multiple myeloma is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
You may also be interested in...
Rozanolixizumab & Biosimilar Ustekinumab Among Raft Of New Drugs Filed In EU
The European Medicines Agency’s latest list of drugs under review for potential marketing approval includes a second generalized myasthenia gravis treatment from UCB and what could become the first biosimilar version of Stelara in the EU.
New EU Filings Include First Self-Administered Treatment For Myasthenia Gravis
UCB’s zilucoplan for treating gMG is among the latest new drugs that the European Medicines Agency has started reviewing for potential EU marketing approval.
Novel Brain Penetrant For Treating X-ALD Among Raft Of New EU Filings
Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.